ALPCO Launches STELLUX Chemiluminescent Human Insulin ELISA
Summary
“With a broader dynamic range and greater sensitivity than anything else in the commercial market, our chemi Human Insulin ELISA will prove to be beneficial to all our customers, but in particular, islet cell researchers,” explains ALPCO’s VP of Scientific Operations, Martin Blankfard.The next STELLUX™ products to launch will include assays for total and intact Proinsulin, C-peptide, and GLP-1.” “Our R&D team continues to deliver new technologies that assist our customers in overcoming the challenges they face in their research endeavors,” adds ALPCO’s President, Sean Conley.ALPCO’s product portfolio continues to expand and includes applications for immunoassay, HPLC, LC-MS/MS, antibodies, recombinant proteins, and flow cytometry reagents.Holding true to ALPCO’s ’s goal for the STELLUX™ line, this new ELISA provides superior sensitivity at 2 pg/mL across a wide dynamic range of 5 – 30,000 pg/mL, with results in under two hours.“With a broader dynamic range and greater sensitivity than anything else in the commercial market, our chemi Human Insulin ELISA will prove to be beneficial to all our customers, but in particular, islet cell researchers,” explains ALPCO’s VP of Scientific Operations, Martin Blankfard.The next STELLUX™ products to launch will include assays for total and intact Proinsulin, C-peptide, and GLP-1.”“Our R&D team continues to deliver new technologies that assist our customers in overcoming the challenges they face in their research endeavors,” adds ALPCO’s President, Sean Conley.